We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 50,000 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2018 15:29 | One thing is for sure. With the former top brass of AZ putting their name to Nuvec, there is going to be a lot more attention given to Nuvecs progress at a time when it is being marketed to the world. | hughwilson | |
08/3/2018 14:31 | Good to see you too indeedee Urigem. | escapetohome | |
08/3/2018 14:24 | $178 billion ! 0.1% of that would make this a 100 bagger company - pie in the sky at the moment, but going in the right direction | urigem | |
08/3/2018 14:21 | wheyhey! nice to see you here escape | urigem | |
08/3/2018 14:19 | BBBBBBBBLLLLLLLLLUUU | escapetohome | |
08/3/2018 14:08 | More press coverage: | hughwilson | |
08/3/2018 13:49 | From Twitter AIM CHAOS#N4P Nuvec growing into a larger beast than I had ever imagined back in 2016! Former Senior Research Scientist at Astra Zeneca to lead its development from now; other major partners on the horizon (Far East and Europe); and total addressable market for Nuvec estimated at $178 bn! | urigem | |
08/3/2018 13:47 | Of the other positive news, the appointment of Andrew Leishman to head up Nuvec shows just how important this division is becoming within the company. The company state that there are no other silica nanoparticle approved products on the market so Nuvec is ahead in what is a $178 billion market and explains the bringing in of the big guns to push the project ahead. Many more positives and Nuvec now being marketed throughout Europe in a few days. All positive stuff. | hughwilson | |
08/3/2018 13:40 | With reference to Japan, investors should note that in today's RNS the company state that they are progressing talks with Japanese contacts. As per previous news they have three months support from the British Embassy in Japan to support such talks so I am expecting results within that timeframe. | hughwilson | |
08/3/2018 13:35 | Hugh’s awfully quiet today!! | eddie_yates | |
08/3/2018 13:10 | O/T I was initially tipped off on N4P on the OPTI bb, and I recommend you guys now take a look over there. Another cracking deal was announced earlier this week but doesn't seem to be fully appreciated by the market - yet. Very low cost business model like N4P. Excellent proactive interview with CEO released today. | parob | |
08/3/2018 13:02 | Yasharad, I would guess a combination of impatient traders disappointed that deals haven't come out of Japan, combined with mms promoting sells. We all know this is a solid company and that deals with these companies do not happen over night. They are proving up to everyone the true value of nuvec. Just will take several months to do so. Meanwhile, I do believe there will be rises once the traders are gone. After all, this news deserves a corresponding strengthened SP:))) dyor | ch1rp | |
08/3/2018 12:45 | Andrew Leishman: Andrew Leishman Ph.D., Director With over 15 years in the biotechnology and pharmaceutical industry Andrew has led projects seeking to deliver therapies targeting components of the immune system. He has worked for various small, medium, and large companies and helped deliver agents that are undergoing clinical trials across several therapy areas. Andrew has a strong understanding of the research and development process for small compound, biological, RNA, and cellular approaches which spans target identification/valid | urigem | |
08/3/2018 12:26 | Well done Urigem & best of luck Here's hoping for 70p by June | eddie_yates | |
08/3/2018 12:24 | Been buying more today, really pleased with the price, increased my holding by about 10% 11094197643952541293 | urigem | |
08/3/2018 12:21 | I cant understand the price drop. Fair enough about the rns which didnt have enough enough info to support a higher jump. But it also didnt have any negative information too. The aims that they have described and they are going to achieve in their research for dna/rna vaccines delivery are easily achievable. In an active research team, it shouldnt take more than a few months to transfect human primary cells with the novex system, to look at its toxicity etc. So why price drop? | yasharsad | |
08/3/2018 12:02 | How about some N4P magic this afternoon:))) | ch1rp | |
08/3/2018 10:40 | Ok thanks scotty lol | jakleeds | |
08/3/2018 10:30 | Need more concrete news on the commercial partnerships IMO....to move this materially | qs99 | |
08/3/2018 10:25 | jak he aint bought anymore just a change in voting rights from 19% to 18.3% due to the extra shares from the exercised warrants | scotty1 | |
08/3/2018 10:24 | Space robot just tweeted:#N4P red after a very bullish RNS this AM. You can't make it up!I'd just like to share this chart from a previous big update for Nuvec on 8th Nov.On the day of the RNS release, share price dropped over 8%! However, the very next day it rose 25% and continued the rise for 3 days...? | ch1rp | |
08/3/2018 10:20 | He’s not stupid ... | jakleeds | |
08/3/2018 10:20 | NT buys more shares. That’s good news ... | jakleeds | |
08/3/2018 10:03 | This is about the right level, no news. | escapetohome | |
08/3/2018 09:32 | Another puff piece rns, no difference in outlook now to when they were 11p. Go you rampers, do your best :) | rathean |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions